Nitro "pohl" Infus Voor Perfusorpompsystemen (Glyceryl Trinitrate)

Glyceryl trinitrate acts as a nitric‑oxide donor. Once administered, it releases nitric oxide, which activates guanylate cyclase in vascular smooth‑muscle cells. This raises cyclic GMP levels, causing smooth‑muscle relaxation, venous pooling, reduced preload, arterial dilation, and ultimately a decrease in myocardial oxygen demand and systemic blood pressure.

The specific infusion rate and total dose of Nitro "pohl" Infus are determined by the prescribing clinician based on the patient’s condition, response, and monitoring parameters. Healthcare professionals adjust the infusion to achieve the desired hemodynamic effect while observing safety guidelines.

Safety data for glyceryl trinitrate during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with obstetric specialists.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Nitro "pohl" Infus delivers glyceryl trinitrate intravenously, offering rapid onset and precise titration, which can be advantageous over oral or sublingual nitrates such as isosorbide dinitrate. While both classes share the same mechanism, the IV formulation allows immediate blood‑pressure control in acute settings, whereas oral agents are suited for chronic management.

Store the infusion solution below 25 °C in its original packaging, protecting it from light and moisture. Avoid freezing or shaking the container. Ensure the product is kept in a secure, temperature‑controlled environment until it is prepared for administration.

The product is administered as an intravenous infusion, typically via a calibrated infusion pump or controlled drip set. Healthcare professionals connect the solution to a sterile IV line, set the prescribed infusion rate, and monitor the patient’s vital signs throughout the administration period.

Serious risks include profound hypotension that can lead to shock, methemoglobinemia which impairs oxygen delivery, myocardial infarction in susceptible individuals, severe allergic reactions such as anaphylaxis, syncope, and potentially life‑threatening cardiac arrhythmias. Continuous hemodynamic monitoring is essential.

Contraindications include patients with severe aortic stenosis, known hypersensitivity to nitrates, concurrent use of phosphodiesterase‑5 inhibitors, and those with uncontrolled hypotension. Caution is also advised for individuals with anemia, elevated intracranial pressure, or recent use of other potent vasodilators.